Last updated: July 17, 2026

Application No. 18/717,529

PHARMACEUTICAL COMBINATION COMPRISING ABEMACICLIB AND A PI3K AND/OR A MTOR INHIBITOR FOR THE TREATMENT OF MANTLE CELL LYMPHOMA

Non-Final OA

Filed

Jun 07, 2024

Priority

Dec 14, 2021 — provisional 63/289,300 +1 more

Examiner

VISHNYAKOVA, ELENA VLADIMIROVNA

Art Unit

Tech Center

Assignee

Board of Regents of the University of Texas System

OA Round

1 (Non-Final)

This examiner grants 61% of cases after interview

— +70.6% interview lift. A telephonic interview to clarify the technical implementation could significantly improve the outcome.

Based on 31 resolved cases, 2023–2026

Examiner Intelligence

VISHNYAKOVA, ELENA VLADIMIROVNA View full profile →

Grants 61% of resolved cases

Career Allowance Rate

19 granted / 31 resolved

+1.3% vs TC avg

Strong +71% interview lift

Without

With

+70.6%

Interview Lift

resolved cases with interview

Typical timeline

2y 11m

Avg Prosecution

36 currently pending

Career history

Total Applications

across all art units

Statute-Specific Performance

§103

53.1%

+13.1% vs TC avg

§102

3.9%

-36.1% vs TC avg

§112

4.7%

-35.3% vs TC avg

Black line = Tech Center average estimate • Based on career data from 31 resolved cases

Prosecution Timeline

Jun 07, 2024

Application Filed

May 27, 2026

Non-Final Rejection mailed (current)

Precedent Cases

Applications granted by this same examiner with similar technology

18/004,504

Patent 12678446

BENZODIAZEPINE DERIVATIVES USEFUL IN TREATING A RESPIRATORY SYNCYTIAL VIRUS INFECTION

3y 6m to grant Granted Jul 14, 2026

19/177,218

Patent 12673941

TERTIARY AMIDE DERIVATIVES SUBSTITUTED WITH 4-MEMBERED RING STRUCTURE

1y 2m to grant Granted Jul 07, 2026

18/920,528

Patent 12668599

HETEROBIFUNCTIONAL COMPOUNDS AND METHODS OF TREATING DISEASE

1y 8m to grant Granted Jun 30, 2026

18/267,330

Patent 12655091

N-BENZYL-ALPHA-AMINOAMIDES AS ANAPHASE-PROMOTING COMPLEX/CYCLOSOME (APC/C) INHIBITORS

3y 0m to grant Granted Jun 16, 2026

19/072,656

Patent 12624033

KRAS INHIBITORS

1y 2m to grant Granted May 12, 2026

Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.

Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2

Expected OA Rounds

61%

Grant Probability

99%

With Interview (+70.6%)

2y 11m (~10m remaining)

Median Time to Grant

Low

PTA Risk

Based on 31 resolved cases by this examiner. Grant probability derived from career allowance rate.